GLP-1 drug after clot removal for stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests if adding a GLP-1 receptor agonist (a type of diabetes medicine that also helps blood vessels) to standard clot removal can improve recovery after a severe stroke. It is for people who had a clot removal for a large artery blockage and can start the drug within 6 hours.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You had a mechanical clot removal (endovascular thrombectomy) for a large artery blockage in the front part of your brain.
- Your stroke symptoms are moderate to severe (NIHSS score 6 or more).
- You were independent before the stroke (could do daily activities without help).
- You can start the study drug within 6 hours after your clot removal procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if adding an interleukin-6 receptor inhibitor (a drug that reduces inflammation) to standard emergency clot removal can improve recovery for people with a severe stroke affecting the back part of the brain (posterior circulation). It is for patients who need urgent treatment within 24 hours of symptom onset.
This study tests a medicine (a GLP-1 receptor agonist) given along with the standard clot-removal procedure for people who have had a severe stroke from a large blockage. The goal is to see if the medicine helps improve recovery by protecting the brain.
This trial tests if semaglutide, a diabetes drug, can improve brain recovery after a stroke when given within 24 hours of symptom onset and before a clot-removal procedure. It may help reduce disability and improve neurological outcomes.
This study tests whether a GLP-1 receptor agonist (a diabetes/weight-loss medication) can help reduce brain damage and improve recovery after a specific type of spontaneous brain bleed. The medication may reduce inflammation and protect brain tissue in the early hours after bleeding.
This Phase 2 study tests whether a semaglutide injection given under the skin soon after an acute ischemic stroke can improve recovery. It may help reduce disability, especially if treatment starts within about 4.5 hours of symptom onset.
This trial tests a new medicine (glenzocimab) given along with standard clot-removal procedure for people who had a stroke with a large area of brain damage. The goal is to see if the medicine helps improve recovery.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.